Glazer Capital LLC’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Glazer Capital LLC’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-266,085	Closed	-$2.65M	–	863
2021 Q3	$2.65M	Sell	266,085 -7,102	-3%	-$70.5K	0.05%	363
2021 Q2	$2.72M	Sell	273,187 -108,499	-28%	-$1.09M	0.04%	392
2021 Q1	$3.8M	Buy	381,686 +18,004	+5%	+$192K	0.05%	376
2020 Q4	$3.93M	Sell	363,682 -62,054	-15%	-$639K	0.14%	167
2020 Q3	$4.42M	Buy	+425,736	New	+$4.42M	0.22%	117

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Glazer Capital LLC's STLN Position: Q4 2021 in Review

Glazer Capital LLC sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 266,085 shares — an estimated $2.65M sold.

Glazer Capital LLC first reported a position in STLN in Q3 2020 and held it in 5 quarters. The position peaked at $4.42M in Q3 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

Glazer Capital LLC reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Glazer Capital LLC sold 266,085 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $2.65M.
Glazer Capital LLC first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Glazer Capital LLC's Starling Oncology Institute, Inc. Common Stock position peaked at $4.42M in Q3 2020.
21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on Glazer Capital LLC's 13F filing for Q4 2021, filed 14 Feb 2022.